상세 보기
Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
- Welslau, M.;
- Ghia, P.;
- Pluta, A.;
- Wach, M.;
- Lysak, D.;
- ... Lee, J. H.;
- 외 15명
Citations
WEB OF SCIENCE
0- 제목
- Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
- 저자
- Welslau, M.; Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Kozak, T.; Simkovic, M.; Kaplan, P.; Kraychok, I; Illes, A.; de la Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E. J.; Lee, J. H.; Wang, D.; Patel, P.; Quah, C.; Jurczak, W.
- 발행일
- 2020-10
- 유형
- Meeting Abstract
- 권
- 43
- 호
- SUPPL 4
- 페이지
- 71 ~ 72